User login
Enter your username and password here in order to log in on the website:
Keywords
- ABPA_Aspergillus
- accompanying diseases
- air-improving devices
- allergy
- animals_pets
- antibiotic therapy
- asthma
- complementary medicine
- covid-19
- diabetes
- diagnostics
- drugs side effects
- drugs under development_genetic therapy
- ENT
- general aspects
- genetics
- health care
- hepatobiliary disease
- hygiene
- i.v.-lines
- inhalation
- lung
- microbiology
- miscellaneous
- modulator therapy
- MRSA
- nutrition and GI problems
- oxygen supplementation_therapy
- physiotherapy
- Pseudomonas aeruginosa
- psychosocial
- public facilities
- recreational activities
- reproduction
- research
- social law
- sport
- swine flu_novel influenza
- transplantation
- travelling
- vaccination
- ventilation
Topics
- Ivacaftor-lumacaftor combination in F508del homozygous patients
- Could you give us some details for the double deltaF508 mutation? Is the Ivacaftor - lumacaftor combination study positive and in that case, how long will it take until market authorization for those drug and to treat a large proportion of sick patients. Thank you in advance for your response.
- 10.09.2014
- Ivacaftor and Lumacaftor
- The results of the phase 3 study have been published a few days ago. There were slight improvements in the 24-weeks study. How can I judge the resutls realistically for the future (timely manner, in case of long-term intake change of the mean life expectancy)? Many thanks for your time
- 21.08.2014
- Colloidal silver
- Can colloidal silver be taken for fighting bacteria in case of CF and can it also be inhaled? Is there any recent research?
- 21.08.2014
- Kalydeco® and body height
- Dear expert team, I have already wrote to you once concerning the off-label use of Kalydeco® with my son Till. He is taking now Kalydeco® for 10 weeks. He is 8-years old and has the mutation 1717 1G>A and the gating mutation S549R. Kalydeco® has a very good effect in him without negative side ...
- 18.08.2014
- Last results of the phase 3 cinical trial VX661 and ivacaftor
- Hello could you inform us regarding results of the clinical phase 3 which has just ended with patients homozygous for the F508del mutation and performed by the Vertex company. Thank you
- 29.07.2014
- Phage therapy
- Ten years ago I have already sent a question to Vaincre la mucoviscidose (French CF patient organization) concerning the subject without a really satisfactory answer. While antibiotic resistance is becoming a social problem why isn't the use of phage therapy further developed, even if the results ...
- 29.07.2014
- Vaccine against Pseudomonas aeruginosa
- Hello There was a clinical trial for Pseudomonas vaccine. What are the news about this clinical trial? Are results available? Thank you.
- 29.07.2014
- F508del heterozygous- first recognitional breakthrough?
- Hello, did I get it right from the English that for the first time there has been a significant improvement in the usage combination VX-661 and KALYDECO® (Ivacaftor) in case of F508del heterozygous patients "with/independent" of G551D? That sounds like a breakthrough for the heterozygous ...
- 28.07.2014
- Drugs for delF508
- Hello, I have recently visited the annual meeting in Bad Soden, Germany. I have heard there, that Kalydeco® together with a potentiator is said to be licensed already in June 2014. Short-dated also a liquid for children is said to come on the market. Did I get this right? Does this mean the ...
- 21.07.2014
- Results from Vertex clinical trial for patient with delF508 mutation
- Hello I’m a CF patient and I’m carrying 2 different mutations: delF508 and 1717-1GA of exon 11. I would like to know if you have the results of the Vertex‘s clinical trials. Are they encouraging? If not, when will they be available? Best regards
- 14.07.2014